Stockscreener 앱 받기
26.35
0.94%
-0.25
시간 외 거래:
26.35
Pacira Biosciences Inc 주식(PCRX)의 최신 뉴스
Pacira (PCRX) Up 6.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance
(PCRX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Pacira BioSciences stock update with limited verified data - AD HOC NEWS
Truist Financial Initiates Pacira BioSciences(PCRX.US) With Buy Rating - Moomoo
Pacira BioSciences Inc (PCRX) Stock Up 3.5% and Still Undervalued -- GF Score: 81/100 - GuruFocus
Foster & Motley Inc. Buys New Holdings in Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira (PCRX) Q2 2026 Results: Reported EPS Tops Expectations in Latest Trading; Post-Earnings: The Stock Gains 1.67% for the Current SessionBalance Sheet Strength - Vinanet
Rice Hall James & Associates LLC Purchases Shares of 93,396 Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira BioSciences Inc (PCRX) Chief Medical Officer Jonathan Slo - GuruFocus
Pacira BioSciences (NASDAQ:PCRX) Insider Jonathan Slonin Sells 3,040 Shares of Stock - MarketBeat
Pacira BioSciences (PCRX) CMO sells 3,040 shares in 10b5-1 plan - Stock Titan
Pacira (PCRX) Daily Price Brief: Records a 2.17% Increase to $23.75 in Latest Trading; Technical Focus: $22.56 and $24.94 Define the Nearby Reference Levels on the DayBPI Bull Correction - vinanet.vn
Pacira BioSciences (NASDAQ: PCRX) faces $70.6K share sale in 2026 - Stock Titan
Pacira BioSciences (NASDAQ:PCRX) Coverage Initiated at Truist Financial - MarketBeat
Truist Financial Upgrades Pacira BioSciences(PCRX.US) to Buy Rating, Raises Target Price to $30 - Moomoo
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Pacira Biosciences (NASDAQ:PCRX): A Value Play with Fundamentals Intact - ChartMill
Barclays Maintains Pacira BioSciences(PCRX.US) With Hold Rating, Maintains Target Price $25 - Moomoo
Empowered Funds LLC Buys 49,171 Shares of Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira BioSciences (NASDAQ:PCRX) Lowered to "Buy" Rating by Wall Street Zen - MarketBeat
Wedge Capital Management L L P NC Purchases New Stake in Pacira BioSciences, Inc. $PCRX - MarketBeat
Assenagon Asset Management S.A. Acquires Shares of 101,429 Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira BioSciences (PCRX) Is Down 7.1% After Advancing PCRX-201 Gene Therapy With Positive Phase 1 Data - Sahm
Pacira BioSciences, Inc. (PCRX) Investor Outlook: Navigating a 22.80% Potential Upside in Non-Opioid Solutions - DirectorsTalk Interviews
J.P. Morgan Maintains Pacira BioSciences(PCRX.US) With Sell Rating, Maintains Target Price $23 - Moomoo
Hennion & Walsh Asset Management Inc. Buys 48,124 Shares of Pacira BioSciences, Inc. $PCRX - MarketBeat
Is Pacira BioSciences (PCRX) Quietly Reframing Its Non‑Opioid Strategy Around PCRX‑201 Gene Therapy? - Yahoo Finance
Pacira BioSciences: Reimbursement Is Turning An Old Franchise Into A New Growth Platform - Seeking Alpha
Pacira BioSciences (NASDAQ:PCRX) Upgraded by Wall Street Zen to Strong-Buy Rating - MarketBeat
State Street Corporation (NYSE: STT) discloses 5.2% ownership in Pacira BioSciences - Stock Titan
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Pacira BioSciences, Inc. (PCRX) Stock forecasts - Yahoo Finance UK
Pacira BioSciences (PCRX) Could Be 35% Undervalued On Phase 1 Gene Therapy Progress - Yahoo Finance
Here's What Analysts Are Forecasting For Pacira BioSciences, Inc. (NASDAQ:PCRX) After Its Second-Quarter Results - Moomoo
Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases - The Manila Times
Pacira BioSciences, Inc. $PCRX Shares Purchased by Pacer Advisors Inc. - MarketBeat
Pacira BioSciences, Inc. (PCRX) Stock Forecasts - Yahoo! Finance Canada
Pacira BioSciences, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:PCRX) 2026-08-05 - Seeking Alpha
Pacira BioSciences (NASDAQ:PCRX) Trading Down 7.9%Should You Sell? - MarketBeat
Royal Bank Of Canada Forecasts Strong Price Appreciation for Pacira BioSciences (NASDAQ:PCRX) Stock - marketbeat.com
H.C. Wainwright Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Maintains Target Price $38 - Moomoo
Pacira Q2 Earnings & Revenues Beat, 2026 Sales Outlook Cut - The Globe and Mail
Pacira BioSciences, Inc. Stock 12‑Month Price Target Raised to $30, Implies 9% Upside - TradingView
PCRX Maintained by Needham -- Price Target Raised to $33.00 - GuruFocus
RBC Adjusts Price Target on Pacira Biosciences to $25 From $24, Maintains Sector Perform Rating - Moomoo
Pacira BioSciences (NASDAQ:PCRX) Price Target Raised to $33.00 - MarketBeat
Pacira BioSciences, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Pacira BioSciences Reports Second Quarter 2026 Financial Results - The Manila Times
Pacira BioSciences Inc (PCRX) (Q2 2026) Earnings Call Highlights: Revenue Growth and Strategic Pivots - GuruFocus
Pacira BioSciences Inc (PCRX) (Q2 2026) Earnings Call Highlights: Revenue Growth and Strategic ... - Yahoo Finance
PCRX SWOT Analysis: Strong Financial Recovery and Growth Potential Revealed in 10-Q Filing - GuruFocus
Earnings call transcript: Pacira BioSciences posts solid Q2 2026 revenue beat - Investing.com
Pacira BioSciences Q2 Earnings Call Highlights - TradingView
Is Pacira BioSciences Inc (PCRX) Undervalued After Q2 Earnings B - GuruFocus
Transcript : Pacira BioSciences, Inc., Q2 2026 Earnings Call, Aug 04, 2026 - marketscreener.com
Pacira Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Pacira BioSciences, Inc. 2026: Revenue $192.4M, EPS $0.12— 10-Q Summary - TradingView
Pacira BioSciences (NASDAQ: PCRX) earns Q2 profit and sells iovera business - Stock Titan
Q2 2026 Pacira Biosciences Inc Earnings Call Transcript - GuruFocus
Earnings Flash (PCRX) Pacira BioSciences, Inc. Posts Q2 Adjusted EPS $0.73 per Share, vs. FactSet Est of $0.65 - marketscreener.com
Pacira BioSciences Q2 revenue rises 6% to $192.4 million - Quiver Quantitative
Pacira BioSciences Q2 2026: Revenue $192.4M, GAAP Net Income $4.7M, Adjusted EBITDA $48.7M - TradingView
BRIEF-Pacira Biosciences Q2 Revenue USD 192.4 Million Vs. IBES Estimate USD 190.8 Million - TradingView
Pacira BioSciences, Inc. (PCRX) Stock Analysis: A Look at Growth Potential and Strategic Positioning - DirectorsTalk Interviews
1.66%
0.33%
자본화:
|
볼륨(24시간):